Barclays Maintains Overweight on Sempra, Lowers Price Target to $90

Benzinga Newsdesk www.benzinga.com Negative 77.1%

Neg 77.1% Neu 0% Pos 0%

Barclays analyst Nicholas Campanella maintains Sempra (NYSE:SRE) with a Overweight and lowers the price target from $103 to $90.